NIPENT, manufactured by Hospira, is a brand name for the drug pentostatin, which is a chemotherapeutic agent used primarily in the treatment of hairy cell leukemia, a rare type of cancer that affects the blood and bone marrow. Pentostatin works by inhibiting an enzyme necessary for the growth and proliferation of cancer cells, thereby slowing or stopping the progression of the disease. It is administered intravenously and is known for its specificity in targeting certain types of cancer cells, which can lead to a reduction in side effects compared to other chemotherapy drugs. However, patients receiving NIPENT may still experience side effects, and its use is carefully monitored by healthcare professionals to manage any adverse reactions and to ensure the effectiveness of the treatment.